U.S. Beverage Stock News

NasdaqGS:CME
NasdaqGS:CMECapital Markets

Should CME Group’s Strong Q2 2026 Results and Buybacks Prompt Action From CME (CME) Investors?

CME Group Inc. recently reported past second-quarter 2026 results, with revenue of US$1,706.2 million and net income of US$1,041.8 million, alongside higher earnings per share compared with the same period a year earlier. For the first half of 2026, CME Group delivered higher revenue and net income while completing a US$1,495.75 million buyback covering 1.48% of its shares, highlighting active capital returns alongside operational performance. Next, we’ll examine how this earnings...
NasdaqGS:TSEM
NasdaqGS:TSEMSemiconductor

Tower Semiconductor (TSEM) Expands In Japan As AI Demand Meets An Undervalued Narrative

Tower Semiconductor (TSEM) has announced a dual track expansion of its 300mm Silicon Photonics, Silicon Germanium, and advanced packaging capacity in Japan, backed by government grants and aimed at long term AI and data center demand. See our latest analysis for Tower Semiconductor. The expansion update arrives after a volatile stretch for Tower Semiconductor, with the share price falling 10.39% on the day to US$233.37 but still showing firm upward momentum through a 20.57% 90 day share price...
NYSE:PATH
NYSE:PATHSoftware

UiPath (PATH) Stock Has Weak Returns But Cash Flow Looks Strong

UiPath stock has fallen about 82% over the past five years. Current valuation checks suggest the shares now trade at a discount to what the company’s cash flows may justify, creating a clear tension between a weak long term return profile and an intrinsic value estimate that points to upside. Over five years, UiPath shareholders have seen the stock decline around 82%. This puts the recent valuation debate in the context of a long period of weak returns. The recent AI driven pricing contract...
NasdaqGS:CASH
NasdaqGS:CASHBanks

How Lower Income, New EPS Targets and Credit Probes At Pathward Financial (CASH) Has Changed Its Investment Story

On July 22, 2026, Pathward Financial, Inc. reported lower quarterly net interest income of US$112.91 million and net income of US$28.97 million, updated its fiscal 2026 EPS guidance to US$7.80–US$8.20, introduced 2027 EPS guidance of US$9.50–US$10.00, and detailed completion of a share repurchase totaling 3,872,821 shares for US$303.85 million. A securities law firm has since opened an investigation into Pathward’s disclosures around rising nonperforming loans and renewable energy...
NasdaqGS:CVBF
NasdaqGS:CVBFBanks

Is CVB Financial (CVBF) Cheap After Mixed Earnings Signals?

Mixed earnings signals at CVB Financial CVB Financial (CVBF) recently reported second quarter and six month results that combined higher net interest income with slightly lower net income and earnings per share, giving investors a mixed picture of profitability and growth. See our latest analysis for CVB Financial. Against this latest earnings release and the recent board appointment of Michael J. Maddox, CVB Financial's recent momentum is positive, with a 10.10% 90 day share price return and...
NYSE:PBI
NYSE:PBICommercial Services

Pitney Bowes (PBI) Could Be 4% Overvalued As New Board Appointment Draws Focus

Pitney Bowes (PBI) drew investor attention after appointing La Vonda Williams to its Board of Directors, adding nearly two decades of finance and operations experience to the company’s recently formed Strategic Review Committee. See our latest analysis for Pitney Bowes. The recent appointment to Pitney Bowes' Strategic Review Committee comes after a period where momentum has shifted, with a 73.09% year to date share price return and a very large 3 year total shareholder return of 405.45%...
NYSE:MAS
NYSE:MASBuilding

Will Masco’s New Enterprise CMO Role Reshape MAS’s Brand‑Led Investment Narrative?

Masco Corporation recently appointed Brad Hiranaga as its first Chief Marketing Officer, reporting directly to CEO Jon Nudi and joining the Executive Committee to lead enterprise-wide brand growth, marketing, commercial excellence, digital acceleration and customer capabilities. By creating a CMO role and hiring a leader with more than 25 years of brand-building experience across consumer, hospitality and outdoor sectors, Masco is signaling a fresh emphasis on sharpening its portfolio of...
NasdaqGS:SIGI
NasdaqGS:SIGIInsurance

Is Selective Insurance Group (SIGI) Undervalued On Strong Q2 Results?

Why Selective Insurance Group Stock Is Back on Investors’ Radar Selective Insurance Group (SIGI) moved into focus after reporting second quarter 2026 results that included higher revenue and net income, along with continued dividends and share repurchases that highlight current capital return priorities. See our latest analysis for Selective Insurance Group. At a share price of $96.33, Selective Insurance Group has seen a 12.52% 90 day share price return and a 25.33% 1 year total shareholder...
NYSE:BYD
NYSE:BYDHospitality

Boyd Gaming (BYD) Q2 Results Put Its Valuation Narrative Under Closer Scrutiny

Mixed Q2 Earnings Put Boyd Gaming Stock Under Closer Scrutiny Boyd Gaming (BYD) is drawing fresh attention after second quarter results showed sales and total revenue roughly in line with last year, while net income and earnings per share from continuing operations declined. See our latest analysis for Boyd Gaming. Following the mixed second quarter, Boyd Gaming’s share price has been relatively muted, with a 30 day share price return of down 2.97% and a year to date share price return of...
NasdaqGS:MKTX
NasdaqGS:MKTXCapital Markets

Is MarketAxess Holdings (MKTX) Undervalued Following Its Recent Share Price Rebound?

MarketAxess Holdings (MKTX) continues to draw investor attention after a period of mixed share performance, with recent gains over the past month contrasting with steeper declines over the past 3 months and the past year. See our latest analysis for MarketAxess Holdings. At a share price of $116.69, MarketAxess Holdings has seen a 1 day share price return of 2.08%, while its 1 year total shareholder return is down 42.77%. This shows recent momentum following a much weaker longer term...
NasdaqGS:MANH
NasdaqGS:MANHSoftware

Manhattan Associates (MANH) Nears Earnings, Is The Stock Fully Valued?

Upcoming Earnings Put Manhattan Associates In Focus Manhattan Associates (MANH) is back on investors’ radar as the supply chain software company heads into its earnings report this Tuesday after the bell, following a prior quarter that topped revenue expectations. See our latest analysis for Manhattan Associates. Manhattan Associates’ recent 10.03% 1 month share price return and 8.09% 3 month share price return contrast with a year to date share price decline of 9.33% and a 1 year total...
NasdaqGS:TLN
NasdaqGS:TLNRenewable Energy

Talen Energy (TLN) Reports Stronger Results, Is The Stock Still Cheap?

The renewed focus on Talen Energy (TLN) centers on its latest quarterly report, which showed higher revenue and net profit, along with a supportive PJM capacity auction outcome that extends contracted revenue visibility for its fleet. See our latest analysis for Talen Energy. Despite the recent PJM auction support and stronger quarterly figures, Talen Energy’s share price has pulled back, with the 30 day share price return down 10.94% and the year to date share price return down 9.28%. At the...
NYSE:ITGR
NYSE:ITGRMedical Equipment

Is Integer Holdings (ITGR) Fairly Valued Following Its Recent Share Price Gains?

Recent Price Moves and Business Scale Integer Holdings (ITGR) has attracted fresh attention after recent trading, with the stock last closing at $98.62. The company has a market value of around $3.3 billion and reports annual revenue of about $1.86 billion. See our latest analysis for Integer Holdings. Recent trading has added to a run of stronger share price returns for Integer Holdings, with a 30 day share price return of 5.04% and a year to date gain of 28.44% even though the 1 year total...
NYSE:TJX
NYSE:TJXSpecialty Retail

TJX Companies (TJX) Could Be 13% Below Fair Value On Stronger Customer Growth

How TJX Companies Stock Has Been Performing TJX Companies (TJX) has delivered a total return of 24.50% over the past year and 85.44% over the past 3 months, with the stock last closing at US$154.22. Shorter term moves have been more muted, with the stock up 0.48% on the day and down 0.95% over the past week. Over the past month the stock shows a decline of 0.78%, and year to date performance is slightly lower by 0.04%. See our latest analysis for TJX Companies. For TJX Companies, the share...
NYSE:TFIN
NYSE:TFINBanks

Triumph Financial (TFIN) Could Be 4% Undervalued After Its Second Quarter 2026 Results

Triumph Financial (TFIN) has drawn investor attention after reporting second quarter 2026 results, with net interest income of US$98.83 million and net income of US$11.37 million from continuing operations. See our latest analysis for Triumph Financial. Following the earnings release, Triumph Financial's share price has eased in the very short term, with a 1-day share price return down 3.75% and a 7-day share price return down 1.21%. However, the 90-day share price return of 13.69%, year to...
NYSE:RBA
NYSE:RBACommercial Services

Is RB Global's Higher Dividend Shaping a New Capital Allocation Story for RBA?

RB Global, Inc. previously announced that on July 21, 2026, its Board of Directors declared a quarterly cash dividend of US$0.33 per common share, payable on September 17, 2026 to shareholders of record on August 25, 2026, and classified as an eligible dividend for Canadian income tax purposes. This dividend decision highlights the company’s ongoing cash returns to shareholders while it continues to operate global marketplaces for commercial assets and vehicles under brands such as Ritchie...
NYSE:FR
NYSE:FRIndustrial REITs

First Industrial Realty Trust (FR) Reports Strong Earnings, Is The Stock Fully Valued?

First Industrial Realty Trust (FR) has drawn fresh attention after reporting second quarter 2026 earnings, with sales of US$194.94 million and net income of US$77.1 million, alongside updated half-year results. See our latest analysis for First Industrial Realty Trust. At a share price of US$66.99, First Industrial Realty Trust has posted a 5.36% 30 day share price return and a 15.70% year to date share price return, while the 1 year total shareholder return of 41.89% points to momentum that...
NasdaqGS:SLM
NasdaqGS:SLMConsumer Finance

Is SLM (SLM) A Bargain As Earnings And Its Dividend Keep Valuation In Focus?

SLM (SLM) shares are in focus after the company reported second quarter 2026 earnings and affirmed a quarterly dividend of $0.13 per share, with payment scheduled for September 15, 2026. See our latest analysis for SLM. At a share price of $24.29, SLM has seen its 7 day and 30 day share price returns decline 4.11% and 4.56% respectively, while the 1 year total shareholder return is down 24.33% but the 3 year total shareholder return is up 60.27%. This suggests longer term holders have fared...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

GeneDx Stock And 2 Testing Companies In Focus After Cyclospora Outbreak

The recent Cyclospora outbreak has pushed food safety, traceability, and testing to the top of investors’ watchlists. When regulators, distributors, and restaurant suppliers come under pressure, attention often shifts to companies that help monitor, test, and verify what moves through the food supply chain. This article looks at how that news may affect a handful of Food Safety & Testing Companies, and why some stocks could be positioned as potential beneficiaries of higher scrutiny and...
NasdaqGS:SRAD
NasdaqGS:SRADHospitality

Consumer Discretionary Stocks to Watch Before Earnings and the Fed Rate Decision

Consumer discretionary stocks are back in focus as markets react to falling oil prices, upcoming mega cap tech earnings, and the Federal Reserve’s next rate call. Lower fuel costs can reshape household budgets, while big tech results and policy signals may influence overall risk appetite. In addition, legal delays around the Paramount and Warner Bros. Discovery deal and new questions about AI rules are adding another layer of uncertainty. This article breaks down how these forces tie into...
NasdaqGS:PECO
NasdaqGS:PECORetail REITs

Stronger Q2 Earnings And Raised Guidance Could Be A Game Changer For Phillips Edison (PECO)

In July 2026, Phillips Edison & Company reported second-quarter revenue of US$189.62 million and net income of US$41.12 million, alongside higher earnings per share versus a year earlier, and raised its 2026 diluted net income guidance to US$0.95–US$0.97 per share from US$0.79–US$0.81. The combination of higher current-period profits and an upward revision to full-year earnings guidance highlights management’s increased confidence in the company’s operating performance. With this stronger...
NYSE:ATEN
NYSE:ATENSoftware

US Tech Stocks Retail Investors May Find More Sheltered From EU Rules And Tariffs

Renewed EU regulation and tariff threats are putting global tech stocks under a spotlight, while many US domestic focused technology companies sit slightly to one side of the crossfire. For investors sorting through the noise, the question is which stocks appear more insulated from these trade and regulatory headlines and which still carry meaningful exposure. This article examines how the latest EU actions and US tariff rhetoric could affect sentiment around certain US tech companies, and...
NasdaqCM:NKTR
NasdaqCM:NKTRPharmaceuticals

Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch?

Nektar Therapeutics (NKTR) has launched the first two global Phase 3 ZENITH AD trials for rezpegaldesleukin in moderate to severe atopic dermatitis, supported by earlier Phase 2b data and FDA Fast Track designations. See our latest analysis for Nektar Therapeutics. The latest rezpegaldesleukin Phase 3 launch comes after a sharp shift in sentiment around Nektar Therapeutics, with a 1-year total shareholder return of 199.05% and a year to date share price return of 62.89%. However, momentum has...
NYSE:QGEN
NYSE:QGENLife Sciences

Is Qiagen (QGEN) A Bargain On Its Infectious Disease Testing Push?

Qiagen (QGEN) is back in focus after highlighting its molecular testing tools in the U.S. cyclosporiasis response and launching a CE-IVDR-certified bloodstream infection and antimicrobial resistance panel for its QIAstat-Dx platform in Europe. See our latest analysis for Qiagen. Qiagen’s recent focus on infectious disease diagnostics comes as the stock trades at US$41.37, with a 90 day share price return of 21.6% but a year to date share price return that is down 13.03%, and a 1 year total...